UB Paderborn / Katalog / Suche / in CDI

Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

European journal of cancer (1990), 2017-02, Vol.72, p.S96-S96

2017

Volltextzugriff (PDF)

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer

Annals of oncology, 2012-03, Vol.23 (3), p.589-597

2012

Volltextzugriff (PDF)

Alteration of red blood cell microrheology by anti-tumor chemotherapy drugs

Biochemistry (Moscow). Supplement series A, Membrane and cell biology, 2016-04, Vol.10 (2), p.135-141

2016

Volltextzugriff (PDF)

Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients

Clinical hemorheology and microcirculation, 2010, Vol.44 (2), p.115

2010

Volltextzugriff (PDF)

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2022-09, Vol.328 (12), p.1223

2022

Volltextzugriff (PDF)

Phase I dose of oral quisinostat, in combination with gemcitabine (G) and cisplatin (Cis) or paclitaxel (P) and carboplatin (Carbo) in patients (pts) with non-small cell lung cancer or ovarian cancer (OC)

Annals of oncology, 2016-10, Vol.27, p.vi123-vi123

2016

Volltextzugriff (PDF)

713 - Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

European journal of cancer (1990), 2017-02, Vol.72, p.S96-S96

2017

Volltextzugriff (PDF)

Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

European journal of cancer supplements, 2008, Vol.6 (7), p.172-172

2008

Volltextzugriff (PDF)

2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer

European journal of cancer supplements, 2007, Vol.5 (4), p.215-215

2007

Volltextzugriff (PDF)

Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

Annals of oncology, 2016-10, Vol.27, p.vi285-vi285

2016

Volltextzugriff (PDF)

6563 POSTER High-dose 130-nanometer albumin-bound paclitaxel in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer

European journal of cancer supplements, 2007, Vol.5 (4), p.376-377

2007

Volltextzugriff (PDF)

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-19-03

2011

Volltextzugriff (PDF)

P5-19-13: A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-19-13

2011

Volltextzugriff (PDF)

Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.275-275

2011

Volltextzugriff (PDF)

Randomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer (CRC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4026-4026

2009

Volltextzugriff (PDF)

Abstract P6-11-02: Final Analysis of NO16853, a Randomized Phase II Non-Inferiority Study of Two Different Doses of Capecitabine in Combination with Docetaxel for Locally Advanced/Metastatic Breast Cancer (LA/MBC)

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P6-P6-11-02

2010

Volltextzugriff (PDF)

First-line phase Ib and II studies of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing therapy for colorectal cancer (CRC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.4100-4100

2008

Volltextzugriff (PDF)

Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.1032-1032

2007

Volltextzugriff (PDF)

Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.7659-7659

2007

Volltextzugriff (PDF)

A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naïve patients with metastatic hormone refractory prostate cancer (HRPC)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5153-5153

2008

Volltextzugriff (PDF)

Hemorheological changes in solid tumor patients after treatment with recombinant erythropoetin

Clinical hemorheology and microcirculation, 2009, Vol.41 (1), p.39

2009

Volltextzugriff (PDF)

Dose escalation study of nab- paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.7132-7132

2006

Volltextzugriff (PDF)

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer

Annals of oncology, 2012-03, Vol.23 (3), p.589

2012

Volltextzugriff (PDF)

A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2010-06, Vol.5 (6), p.852-861

2010

Volltextzugriff (PDF)

The Time Equations and Formula Budgeting in Jointed Model for Higher Education

American journal of educational research (Print), 2015-10, Vol.3 (8), p.1015-1019

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer

Alteration of red blood cell microrheology by anti-tumor chemotherapy drugs

Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial

Phase I dose of oral quisinostat, in combination with gemcitabine (G) and cisplatin (Cis) or paclitaxel (P) and carboplatin (Carbo) in patients (pts) with non-small cell lung cancer or ovarian cancer (OC)

713 - Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer

Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer

Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

6563 POSTER High-dose 130-nanometer albumin-bound paclitaxel in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial

P5-19-13: A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2

Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial

Randomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer (CRC)

Abstract P6-11-02: Final Analysis of NO16853, a Randomized Phase II Non-Inferiority Study of Two Different Doses of Capecitabine in Combination with Docetaxel for Locally Advanced/Metastatic Breast Cancer (LA/MBC)

First-line phase Ib and II studies of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing therapy for colorectal cancer (CRC)

Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)

A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naïve patients with metastatic hormone refractory prostate cancer (HRPC)

Hemorheological changes in solid tumor patients after treatment with recombinant erythropoetin

Dose escalation study of nab- paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC)

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer

A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

The Time Equations and Formula Budgeting in Jointed Model for Higher Education

Suchergebnisse filtern